VSTM

Verastem, Inc.

A biopharmaceutical company focused on fighting cancer, Verastem makes AVMAPKI FAKZYNJA CO-PACK (avutometinib/defactinib), a treatment for a rare form of ovarian cancer called low-grade serous ovarian cancer that received accelerated FDA approval in 2025. It's also developing VS-7375, an oral drug aimed at tumors driven by a common KRAS mutation. Based in the US, the company concentrates on the RAS/MAPK pathway, a key driver in many cancers.